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Pnsulin Therapy Is Associated With Platelet
ysfunction in Patients With Type 2 Diabetes
ellitus on Dual Oral Antiplatelet Treatment
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arco A. Costa, MD, PHD, FACC,* Manel Sabaté, MD, PHD,† Pilar Jimenez-Quevedo, MD,†
osana Hernández, MD, PHD,† Raul Moreno, MD,† Javier Escaned, MD, PHD,†
ernando Alfonso, MD, PHD,† Camino Bañuelos, MD,† Theodore A. Bass, MD, FACC,*
arlos Macaya, MD, PHD,† Antonio Fernandez-Ortiz, MD, PHD†
acksonville, Florida; and Madrid, Spain
OBJECTIVES This study sought to assess the influence of type 2 diabetes mellitus (T2DM) and the impact
of hypoglycemic treatment (insulin vs. noninsulin) on platelet function profiles in patients
treated with dual oral antiplatelet therapy.
BACKGROUND Insulin inhibits platelet aggregation by suppressing the P2Y12 pathway. However, T2DM patients
have a loss of responsiveness to insulin that leads to upregulation of the P2Y12 pathway, increased
platelet reactivity, and reduced responsiveness to antiplatelet agents. Patients with insulin-treated
diabetes mellitus (ITDM) have a more advanced disease status and higher atherothrombotic risk
compared with non-ITDM (NITDM). However, the impact of insulin therapy on platelet
dysfunction in patients treated with P2Y12 antagonists is unknown.
METHODS A total of 201 T2DM and 65 nondiabetic patients with coronary artery disease in a steady
phase of aspirin and clopidogrel treatment were studied. Platelet aggregation was assessed
using agonists specific (6 and 20 M adenosine diphosphate [ADP]) and nonspecific
(6 g/ml collagen and 20 M epinephrine) for the P2Y12 pathway. High shear-induced
platelet reactivity was assessed by means of the PFA-100 system (Dade-Behring Interna-
tional, Miami, Florida).
RESULTS The T2DM patients had platelet aggregation and shear-induced platelet function significantly
increased compared with nondiabetic patients using all assays. Platelet aggregation was increased
in ITDM (n  68) compared with NITDM (n  133) patients after P2Y12-specific stimuli.
Insulin treatment was the strongest predictor of ADP-induced aggregation. Platelet function
profiles were similar between ITDM and NITDM using assays nonspecific to the P2Y12 pathway.
Platelet dysfunction was independent of glycemic control and inflammatory status.
CONCLUSIONS The P2Y12-dependent and -independent pathways of platelet reactivity are altered in T2DM
compared with nondiabetic patients, and ITDM have greater ADP-induced platelet
aggregation compared with NITDM. (J Am Coll Cardiol 2006;48:298–304) © 2006 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.038the American College of Cardiology Foundation
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whe platelet P2Y12 receptor plays a pivotal role in platelet
ggregation (1). Its critical role on thrombosis has been
mphasized by clinical trials showing improvement in long-
erm clinical outcomes of patients treated with the P2Y12
eceptor antagonist clopidogrel (2–4). Patients with type 2
iabetes mellitus (T2DM) are characterized by a prothrom-
otic status (5–7) and seem to benefit most, particularly
hose requiring insulin therapy, from P2Y12 antagonism
ompared with aspirin (8).
Insulin has been shown to inhibit platelet aggregation by
uppressing the P2Y12 pathway in healthy volunteers (9).
owever, such antithrombotic protection is hampered in
2DM patients because their platelets have reduced sensitivity
o insulin (7,10). In addition, the P2Y12 pathway per se is
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or Sanofi-Aventis and Bristol Myers Squibb. He declares to have had full access to
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or publication in the Journal of the American College of Cardiology.H
Manuscript received February 3, 2006; revised manuscript received March 10,
006, accepted March 20, 2006.pregulated in patients with T2DM (10). Overall, these
ndings may explain the reduced responsiveness to P2Y12
ntagonists in patients with T2DM compared with nondia-
etic patients (10,11). Insulin-treated diabetes mellitus
ITDM) patients may represent a diabetic subpopulation with
ore advanced stages of insulin resistance and biological
isorders (12,13). However, the impact of insulin therapy on
latelet dysfunction in patients with T2DM treated with
2Y12 antagonists remains to be demonstrated. In the present
tudy we assessed platelet function profiles in a large cohort of
2DM patients treated with aspirin and the P2Y12 antagonist
lopidogrel, and hypothesize that: 1) T2DM patients have
ncreased platelet aggregation compared with nondiabetic pa-
ients; and 2) platelet P2Y12 dysfunction is more pronounced
n ITDM compared with non-ITDM (NITDM) patients.
ETHODS
atient population. A total of 201 patients with T2DM
ere studied. We defined T2DM according to World
ealth Organization criteria, and patients were classified as
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July 18, 2006:298–304 Diabetes Mellitus and Dual Antiplatelet TreatmentTDM or NITDM (14). Diet-controlled diabetic patients
ere excluded. A control group composed of 65 nondiabetic
atients was also studied. All patients had previously un-
ergone percutaneous coronary intervention and were
reated with dual oral antiplatelet therapy (aspirin plus
lopidogrel). Because pharmacokinetic and pharmacody-
amic profiles vary in the early stages of dual antiplatelet
herapy and several days or weeks may be required to achieve
ull antiplatelet effects (15,16), only patients in their steady
hase of treatment (1 month) were included. All patients
ere treated with the same maintenance doses of aspirin
100 mg/day) and clopidogrel (75 mg/day). Patient compli-
nce with antiplatelet treatment was assessed by interview
nd/or pill counting.
Exclusion criteria were diet-controlled diabetes mellitus,
ombined aspirin and clopidogrel treatment 1 month,
oncomitant use of other antithrombotic drugs (oral anti-
oagulants, dipyridamole, ticlopidine, cilostazol) or nonste-
oidal anti-inflammatory drugs, occurrence of an acute
schemic episode (unstable angina/myocardial infarction/
erebrovascular event) since the time of last coronary inter-
ention, platelet count 125,000/mm3, hematocrit 25%,
r creatinine levels 2.5 mg/dl.
This study complied with the Declaration of Helsinki, it
as approved by the Ethical Committee of the San Carlos
niversity Hospital, and all patients gave their informed
onsent.
lood sampling. Blood samples for platelet function assays
ere collected from an antecubital vein using a 21-gauge
eedle 2 to 4 h after antiplatelet therapy intake. The first 2
o 4 ml of blood were discarded to avoid spontaneous
latelet activation. Platelet function assessments included
latelet aggregation and high shear-induced platelet
eactivity.
Platelet aggregation was performed using light transmit-
ance aggregometry according to standard protocols (11). In
rief, blood was collected in tubes containing 3.8% triso-
ium. Platelet aggregation was assessed using platelet-rich
lasma (PRP) by the turbidimetric method in a 2-channel
ggregometer (Chrono-Log 490 Model, Chrono-Log Cor-
oration, Havertown, Pennsylvania). The PRP was ob-
ained as a supernatant after centrifugation of citrated blood
Abbreviations and Acronyms
ADP  adenosine diphosphate
CADP  collagen/ADP
CEPI  collagen/epinephrine
CT  closure time
HbA1C  hemoglobin A1C
ITDM  insulin-treated diabetes mellitus
NITDM  noninsulin-treated diabetes mellitus
PPP  platelet-poor plasma
PRP  platelet-rich plasma
T2DM  type 2 diabetes mellitust 800 rpm for 10 min. The isolated PRP was kept at 37°C nefore use. Platelet-poor plasma (PPP) was obtained by a
econd centrifugation of the blood fraction at 2,500 rpm for
0 min. The platelet count in PRP was adjusted to the range
f 250,000/l by dilution with autologous plasma when the
latelet count was out of range. Light transmission was
djusted to 0% with PRP and to 100% for PPP for each
easurement. Platelet aggregation was assessed within 2 h
rom blood sampling. Curves were recorded for 5 min, and
latelet aggregation was determined as the maximal percent
hange in light transmittance from baseline using PPP as a
eference. Because clopidogrel is a P2Y12 adenosine diphos-
hate (ADP) receptor antagonist, ADP stimuli (6 and 20 M
DP) were used to assess individual response to clopidogrel
11,17) and test our study hypotheses: ADP-induced
latelet reactivity will be higher in T2DM compared with
ondiabetic patients (hypothesis 1) and in ITDM com-
ared with NITDM patients (hypothesis 2). Agonists not
pecific to the P2Y12 pathway (6 g/ml collagen and 20 M
pinephrine) were also used to assess P2Y12-independent
athways leading to platelet aggregation (17,18).
The PFA-100 (Dade-Behring International, Miami,
lorida) was used to assess shear-induced platelet re-
ctivity (19). The PFA-100 system is a microprocessor-
ontrolled instrument/test cartridge system used to assess
latelet function simulating platelet-based primary hemo-
tasis in vitro. A syringe aspirates citrated whole blood
nder high shear flow conditions (5,000 to 6,000 s1)
hrough a small aperture (150 m) cut into a membrane
laced in the test cartridge. The membrane is coated with
ype I collagen and either 10 g epinephrine bitartrate
CEPI) or 50 g ADP (CADP). The time necessary for the
cclusion of the aperture is defined as closure time (CT).
educed CTs are indicative of increased platelet reactivity
nd vice versa. After 300 s, the process automatically
erminates. Any CEPI-CTs 300 s are indicative of an
ptimal response to antiplatelet therapy (19).
In the cohort of patients with T2DM, hemoglobin A1C
HbA1C) and high-sensitivity C-reactive protein were as-
essed and correlated with platelet function assessments.
tatistical analysis. Variables were analyzed for a normal
istribution with the Kolmogorov-Smirnov test. Normally
istributed variables are presented as mean  standard
eviation. Variables that did not follow a normal distribu-
ion are represented as median and interquartile range.
ategorical variables are expressed as frequencies and per-
entages. Categorical variables were compared by means of
he chi-square test or the Fisher exact test when at least 25%
f values showed an expected cell frequency below 5. The
tudent t test and one-way analysis of variance were used to
ompare continuous variables when these were normally
istributed and the Mann-Whitney U test or Kruskal-
allis test if not normally distributed. Correlation analyses
ere performed according to the Spearman or the Pearson
orrelation coefficient. A multivariate linear regression anal-
sis was performed to identify the independent determi-
ants of platelet aggregation. Variables included in the
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.1) in a univariate model that included age (65 years),
ender, obesity (body mass index [BMI] 30 kg/m2),
moking, hyperlipidemia, hypertension, prior myocardial
nfarction, prior coronary artery bypass surgery, peripheral
asculopathy, and medical therapy (beta-blockers, nitrates,
ngiotensin-converting enzyme inhibitors, lipid-lowering
gents, calcium-channel blockers). A p value  0.05 was
onsidered statistically significant. Statistical analysis was
erformed using SPSS version 11.0 software (SPSS Inc.,
hicago, Illinois).
ESULTS
atient demographics. A total of 201 patients with
2DM with stable coronary artery disease on sustained (1
onth) aspirin and clopidogrel treatment were analyzed:
8 ITDM and 133 NITDM. Demographics of T2DM and
ondiabetic patients are shown in Table 1. There were no
ifferences between groups, except for a higher prevalence of
emale patients, increased age, and higher BMI in patients
ith ITDM. The NITDM patients were treated with either
etformin or sulfonylurea derivatives; insulin-sensitizing
gents appertaining to the family of peroxisome proliferator-
ctivated receptor-gamma receptor agonists were not used in
hese patients.
2DM versus nondiabetic patients. Platelet aggregation
expressed as percentage) profiles presented a normal distri-
ution and were significantly higher in patients with
2DM compared with nondiabetic patients after ADP
M (41.5  14.7 vs. 31.8  14.8; p  0.0001), ADP
0 M (52.9  13.8 vs. 43.0  17.6; p  0.001), 6
g/ml collagen (42.8  18.5 vs. 31.5  18.4; p 
.0001) and 20 M epinephrine (31.8  14.9 vs. 26.4 
1.0; p  0.0015) stimuli. Platelet function values
ssessed by PFA-100 did not follow a normal distribution
Table 1. Demographics of Study Population
(n
Age (yrs)
Gender (male), n (%) 3
Race (Caucasian), n (%) 6
Body mass index 30
Risk factors/past medical history, n (%)
Smoking
Hyperlipidemia 4
Hypertension 4
Prior myocardial infarction 2
Prior coronary artery bypass surgery*
Peripheral vasculopathy 1
Treatment, n (%)
Beta-blockers 4
Nitrates 3
Angiotensin-converting enzyme inhibitors 4
Lipid-lowering agents 5
Calcium-channel blockers 1
Data are presented as the mean value  SD or number (%
analysis of variance test and categorical variables by means of the c
ITDM insulin-treated diabetes mellitus; NDM non-diabetnd are presented as median and interquartile range. The
Ts (expressed in seconds) of CADP (81.0 [70.0 to
01.0] vs. 91.0 [77.5 to 106.2]; p  0.02) and CEPI
182.5 [129.5 to 300.0] vs. 300.0 [157 to 300.0]; p 
.001) cartridges were significantly lower in T2DM,
ndicative of increased platelet reactivity. The CEPI
alues above 300 s were observed less frequently in
2DM (42.5% vs. 66.2%; p  0.001). Overall, nondia-
etic patients had the lowest platelet aggregation and
ighest CT values compared with NITDM and ITDM
Table 2).
TDM versus NITDM. The ADP-induced platelet ag-
regation was significantly higher in ITDM compared with
ITDM patients (Fig. 1). Similarly, shear-induced platelet
eactivity using ADP-containing cartridges (CADP) was
igher in ITDM compared with NITDM as reflected by
heir shorter CTs (75.0 [66.4 to 93.5] vs. 84.0 [71.5 to
03.0]; p 0.02). No differences were observed in collagen-
nduced (43.0  17.6 vs. 42.7  18.9; p  0.9) and
pinephrine-induced (32.0 13.9 vs. 31.2 15.4; p 0.9)
latelet aggregation between ITDM and NITDM patients.
he CEPI-CT (178.0 [122.5 to 300.0] vs. 190.0 [135.5 to
00.0]; p  0.6) were also similar in ITDM and NITDM
atients, as well as the number of patients with CEPI-CT
bove 300 s (39% vs. 44%; p  0.9).
The HbA1C levels were significantly higher in ITDM
ompared with NITDM patients (7.9  1.5 vs. 6.9  1.0;
 0.0001). The HbA1C levels were not correlated with
ny of the platelet function assays performed (r  0.3 for all
ssessments). The CRP levels were not normally distributed
nd were significantly higher (p  0.007) in ITDM (0.39
g/dl [0.24 to 0.75]) compared with NITDM (0.28 mg/dl
0.15 to 0.50]). The CRP levels were not associated with
latelet function. The ITDM had a higher BMI compared
ith NITDM (30.2  4.8 vs. 28.8  3.7; p  0.04);
8)
NITDM
(n  133)
NDM
(n  65) p Value
9 66  9 62  11 0.003
) 100 (75) 51 (79) 0.001
0) 133 (100) 65 (100) NS
4.8 28.8  3.7 27.2  3.3 0.0001
) 17 (13) 11 (17) NS
) 92 (69) 43 (66) NS
) 82 (62) 34 (52) NS
) 66 (50) 29 (45) NS
4 (3) 1 (2) NS
) 18 (13) 9 (14) NS
) 84 (63) 44 (59) NS
) 55 (41) 36 (55) NS
) 92 (69) 43 (66) NS
) 97 (73) 44 (68) NS
) 35 (26) 26 (40) NS
tinuous variables were compared by means of the one-wayITDM
 6
68 
4 (50
8 (10
.2 
7 (10
7 (69
8 (71
9 (43
3 (5)
6 (24
8 (70
2 (47
7 (69
1 (75
8 (27
). Con
hi-square test or Fisher exact test when appropriate ().
es mellitus; NITDM noninsulin-treated diabetes mellitus.
h
f
m
t
A
D
T
c
r
c
i
t
e
N
d
t
s
a
a
d
c
r
u
s
r
p
o
I
r
w
i
l
m
i
s
d
o
m
s
a
I
r
t
r
w
m
g
a
I
F
(
b
coated
T
A
A
A
I
d
s
a
n
c
301JACC Vol. 48, No. 2, 2006 Angiolillo et al.
July 18, 2006:298–304 Diabetes Mellitus and Dual Antiplatelet Treatmentowever, BMI was not correlated with any of the platelet
unction assays performed (r  0.3 for all assessments). In a
ultivariate linear regression analysis, insulin treatment was
he strongest variable associated with both 6 and 20 M-
DP induced platelet aggregation (Table 3).
ISCUSSION
his is the first report on platelet dysfunction in a large
ohort of patients with T2DM treated with the P2Y12
eceptor antagonist clopidogrel and aspirin. Our results
onfirm the hypotheses that: 1) patients with T2DM have
ncreased platelet function compared with nondiabetic pa-
ients, and 2) ITDM patients have reduced clopidogrel
ffects on ADP-induced platelet aggregation compared with
ITDM. Further, our findings suggest that both P2Y12-
ependent and -independent pathways are altered in pa-
ients with T2DM compared with nondiabetic patients, as
hown by increased platelet reactivity to the multiplicity of
gonists used in this study. Pathways leading to platelet
ggregation independent of the P2Y12 receptor, although
ysfunctional in the overall T2DM patients, seem to be
omparable between ITDM and NITDM, because platelet
eactivity to epinephrine and collagen, which do not stim-
late the P2Y12 receptor, was similar between the diabetic
ubgroups. However, ITDM and NITDM differed with
igure 1. Platelet aggregation after 6 and 20 M adenosine diphosphate
Table 2. Platelet Function Profiles of the Stud
ITDM
(n  68)
ADP 6 M (%) 44.4  15.4
ADP 20 M (%) 56.3  14.7
Collagen 6 g/ml (%) 43.0  17.6
Epinephrine 10 M (%) 32.0  13.9
CADP-CT (s) 75.0 [66.4–93.5]
CEPI-CT (s) 178.0 [122.5–300.0]
Platelet aggregation (ADP, collagen, and epinephrine) data w
p values were calculated using one-way analysis of varianc
normally distributed and are presented as as median and in
testing.
ADP adenosine diphosphate; CADP collagen/ADP-
CT  closure time; other abbreviations as in Table 1.ADP) stimuli in noninsulin-treated diabetes mellitus (NITDM; open
ars) and insulin-treated diabetes mellitus (ITDM; solid bars).
aegards to the response to ADP, more specific to the P2Y12
athway.
In vitro studies assessing the impact of insulin on platelets
f healthy volunteers have led to ambiguous findings (9,20).
n a recent report, Ferreira et al. (9) observed that insulin
educes platelet aggregation by inhibiting the P2Y12 path-
ay. In fact, human platelets are the target of the action of
nsulin through specific platelet membrane receptors that
ead to loss of Gi activity (9). This reduces cyclic adenosine
onophosphate suppression, thus inhibiting P2Y12 signal-
ng and reducing platelet reactivity. However, these in vitro
tudies evaluated the effects on platelet function of a single
ose of insulin, whereas in our study we assessed two groups
f T2DM patients with and without chronic insulin treat-
ent. Notably, platelets of T2DM patients have decreased
ensitivity to insulin, leading to reduced P2Y12 inhibition
nd increased platelet reactivity (10). Because patients with
TDM are likely to be at a more advanced state of insulin
esistance, this may explain the enhanced platelet reactivity
o ADP, used to test the responsiveness to the P2Y12
eceptor antagonist clopidogrel, in these patients. Patients
ho have poor glycemic control on oral hypoglycemic
edication require exogenous insulin therapy (13). This
enerally occurs in patients with a longer history of diabetes
nd a more advanced stage of insulin-resistance (12,13).
mportantly, women are more intrinsically insulin resistant
pulation
NITDM
(n  133)
NDM
(n  65) p Value
9.9  14.1 31.8  14.8 0.0001
1.2  13.1 43.0  17.6 0.0001
2.7  18.9 31.5  18.4 0.0001
1.2  15.4 26.4  11.0 0.03
[71.5–103.0] 91.0 [77.5–106.2] 0.005
[135.5–300.0] 300.0 [157–300.0] 0.006
ormally distributed and presented as the mean value  SD;
ng. PFA-100 data (CADP-CT and CEPI-CT) were not
artile range; p values were calculated using Kruskal-Wallis
cartridges; CEPI collagen/epinephrine-coated cartridges;
able 3. Multivariate Linear Regression Analysis of
DP-Induced Platelet Aggregation
Coefficient  95% CI p Value
DP 6 M
Insulin treatment 10.0 4.6–15.4 0.0001
Female gender 3.4 0.2–8.1 0.06
Obesity 3.7 0.3–7.7 0.07
DP 20 M
Insulin treatment 11.1 5.7–16.5 0.001
Obesity 3.8 0.2–7.9 0.02
n this model, ADP (6 and 20 M)-induced platelet aggregation was used as the
ependent variable, and the independent variables included age, gender, obesity,
moking, hyperlipidemia, hypertension, prior myocardial infarction, prior coronary
rtery bypass surgery, peripheral vasculopathy, and medical therapy (beta-blockers,
itrates, angiotensin-converting enzyme inhibitors, lipid-lowering agents, calcium-
hannel blockers). Age, gender, obesity, and insulin-treatment (p  0.1 in univariatey Po
3
5
3
84.0
190.0
ere n
e testi
terqunalysis) were included in the final multivariate model.
CI  confidence interval; other abbreviations as in Table 2.
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Diabetes Mellitus and Dual Antiplatelet Treatment July 18, 2006:298–304han are men (21,22). Overall, these observations support
he increased age and higher incidence of female patients
ith ITDM in our study. Similar findings have been
eported previously (23–25).
In addition to platelet aggregation, shear-induced platelet
unction was also increased in T2DM platelets. Although
o differences in platelet reactivity were observed between
TDM and NITDM patients using cartridges containing
pinephrine, this was increased with cartridges containing
DP in ITDM. Of note, the PFA-100 cartridges have
educed sensitivity to thienopyridines (19). Therefore it may
e argued whether or not responsiveness to clopidogrel may
e truly revealed by the CADP cartridges. However, to date,
imilar assessments have been primarily performed in non-
iabetic subjects. Because patients with T2DM have a
ysfunctional status of the P2Y12 pathway, they may be
ore sensitive to this assay compared with nondiabetic
atients, and therefore the assay may not only reveal
unctional differences between T2DM and nondiabetic
atients, but, in agreement with the platelet aggregation
ssays, also between ITDM and NITDM. Regardless of the
auses, the overall findings of our multiple platelet function
ssays strongly support the differential responsiveness to
ntiplatelet agents in T2DM compared with nondiabetic
atients.
Poor glycemic control is another important cause of
ncreased platelet reactivity (6,7). Hyperglycemia leads to
onenzymatic glycation of platelet glycoproteins, causing
hanges in their structure and conformation, as well as
lterations of membrane lipid dynamics (26). Importantly,
latelet aggregation can be reduced with tight control of
lucose levels (27). However, no correlation was observed
etween HbA1C levels and platelet function in our study.
otably, our study was conducted in a tightly controlled
iabetic population (the coefficient of variation of HbA1C
evels was only 6%), which led to a limited variability in
bA1C levels. Such a narrow window of HbA1C levels
ay have hindered any correlation with platelet function
ssessments. Individuals with an elevated BMI also have
ncreased platelet reactivity, and platelets from these indi-
iduals have a blunted inhibitory response to insulin (28,29).
ecause in our study patients with T2DM, in particular
TDM, were characterized by elevated BMI, it may be
ypothesized that this may have contributed to our study
ndings. However, no correlation was observed between
latelet function profiles and BMI. Further, in a multivar-
ate analysis, insulin treatment was the strongest predictor of
DP-induced platelet aggregation.
Other mechanisms intrinsic to the diabetic platelet,
hich involve intracellular signaling pathways, play a critical
ole in platelet reactivity. These may include increased
xidative stress leading to enhanced peroxidation of arachi-
onic acid to form biologically active isoprostanes (30),
ncreased platelet turnover (31), increased cytosolic levels of
alcium (32), insulin resistance, and upregulation of the
2Y12 pathway (10). Importantly, the latter two mecha- tisms are strictly interrelated and may become more dys-
unctional with disease progression. Overall, ITDMs are at
more advanced stage of their metabolic disorder, which
ay explain the increase in platelet reactivity to ADP
timuli observed in nondiabetic patients, NITDM and
TDM, respectively (Fig. 2). Further studies testing the
elationship between therapeutic interventions in diabetic
atients, particularly those with ITDM, and platelet aggre-
ation and thrombotic events are warranted.
Recent reports have shown that P2Y12 inhibition with
lopidogrel is associated with anti-inflammatory effects
33,34). Therefore, patients with T2DM may be more
usceptible to the effects of P2Y12 antagonists because of
heir enhanced inflammatory status (35). Although the
echanisms have not been fully elucidated, the P2Y12
eceptor per se has been invoked as a mediator of anti-
nflammatory responses achieved with clopidogrel (35). In
ur study we observed an enhanced inflammatory status in
TDM compared with NITDM, which may be associated
ith dysfunction of the P2Y12 pathway. However, the lack
f correlation between CRP levels and platelet reactivity in
he present study does not support such a hypothesis.
herefore, high CRP levels observed in the ITDM patients
re more likely related to the more advanced disease status
f these patients and the intrinsic proinflammatory effects of
nsulin (36).
herapeutic implications. Treatment with insulin is typ-
cally considered a surrogate of increased atherothrombotic
isk. Previous studies from our group and others were
nable to show differences in platelet reactivity between
TDM and NITDM likely because of limited sample sizes,
hich typically characterize platelet function studies (11).
he prognostic implications associated with enhanced
latelet reactivity, even in patients treated with clopidogrel,
re noteworthy (37–39). Importantly, in this study we
ssessed posttreatment platelet reactivity, which has shown
igure 2. Platelet aggregation after 6 (left) and 20 (right) M adenosine
iphosphate (ADP) stimuli in nondiabetic patients (NDM; dotted bars),
oninsulin-treated diabetes mellitus (NITDM; open bars) and insulin-
reated diabetes mellitus (ITDM; solid bars).o be a better predictor of ischemic risk (39). The seminal
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July 18, 2006:298–304 Diabetes Mellitus and Dual Antiplatelet Treatmentndings from our present functional study may provide a
echanistic explanation to the higher ischemic risk ob-
erved in T2DM patients, especially ITDM, within larger-
cale clinical studies (24,25). In particular, the proinflam-
atory and prothrombotic status that characterizes ITDM
ay explain why these patients have higher rates of reste-
osis, even after drug-eluting stent implantation, as well as
tent thrombosis (40). Aggressive and/or tailored anti-
hrombotic regimens for these patients may be warranted.
andmark results showing a mortality benefit in diabetic
atients and in particular in ITDM with platelet glyco-
rotein IIb/IIIa receptor inhibitors are supportive of the
eed for more aggressive antithrombotic treatment regi-
ens in these patients (25). Whether more potent P2Y12
ntagonism using a higher maintenance dose of clopidogrel
r novel oral P2Y12 antagonists (prasugrel, AZD6140) will
e able to inhibit more efficiently the upregulated P2Y12
athway in platelets of T2DM patients is currently under
nvestigation (41). Ultimately, the use of novel insulin-
ensitizing agents that exert their effects on peroxisome
roliferator-activated receptor-gamma receptors as a thera-
eutic measure of glycemic control may also represent an
mportant adjunctive approach because of their pleiotropic
anti-inflammatory and antithrombotic) effects (42). This is
elated to the ubiquity of insulin resistance, which affects
ultiple cell lines, and underscores how pleiotropic benefits
ay be achieved by overcoming this phenomenon with
hese agents. In the future, individualized and more aggres-
ive therapeutic approaches with multifaceted properties
hould be considered to provide further protection to these
igh-risk patient subsets.
tudy limitations. The present study was not designed to
valuate long-term outcomes. Therefore, despite the known
rognostic implications associated with increased platelet
eactivity, its clinical impact in our study population war-
ants further investigation.
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